MedTrace Logo

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

NCT03671590 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2024-07-19

No results posted yet for this study

Summary

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.

Conditions

Interventions

DRUG

TG-1701

Oral daily dose

DRUG

Umbralisib

Oral Daily Dose

BIOLOGICAL

Ublituximab

IV infusion

Sponsors & Collaborators

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Constantine S. Tam, MD · St. Vincents Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2024-05-21
Completion
2024-05-21
FDA Drug
Yes

Countries

  • Australia
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03671590 on ClinicalTrials.gov